Colonial Trust Co SC Invests $35,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 150 shares of the biopharmaceutical company’s stock, valued at approximately $35,000.

Other hedge funds have also recently bought and sold shares of the company. Larson Financial Group LLC increased its stake in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the period. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $33,000. OFI Invest Asset Management purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $35,000. IFP Advisors Inc grew its stake in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in shares of Alnylam Pharmaceuticals by 6,200.0% during the fourth quarter. Venturi Wealth Management LLC now owns 252 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 248 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ:ALNY opened at $252.00 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $144.73 and a 1-year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market cap of $32.86 billion, a P/E ratio of -116.13 and a beta of 0.17. The firm has a fifty day moving average price of $250.53 and a 200 day moving average price of $254.26.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The business’s revenue for the quarter was up 20.2% on a year-over-year basis. During the same period last year, the business earned ($0.16) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,392 shares of company stock worth $1,875,627. 1.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Citigroup lifted their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a report on Friday, March 21st. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a research note on Friday, April 11th. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.